330 related articles for article (PubMed ID: 28216062)
1. Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study.
Quelch DR; Mick I; McGonigle J; Ramos AC; Flechais RSA; Bolstridge M; Rabiner E; Wall MB; Newbould RD; Steiniger-Brach B; van den Berg F; Boyce M; Østergaard Nilausen D; Breuning Sluth L; Meulien D; von der Goltz C; Nutt D; Lingford-Hughes A
Biol Psychiatry; 2017 Jun; 81(11):941-948. PubMed ID: 28216062
[TBL] [Abstract][Full Text] [Related]
2. Nalmefene attenuates neural alcohol cue-reactivity in the ventral striatum and subjective alcohol craving in patients with alcohol use disorder.
Karl D; Bumb JM; Bach P; Dinter C; Koopmann A; Hermann D; Mann K; Kiefer F; Vollstädt-Klein S
Psychopharmacology (Berl); 2021 Aug; 238(8):2179-2189. PubMed ID: 33846866
[TBL] [Abstract][Full Text] [Related]
3. The effects of nalmefene on emotion processing in alcohol use disorder - A randomized, controlled fMRI study.
Vollstädt-Klein S; Bumb JM; Otto A; Dinter C; Karl D; Koopmann A; Hermann D; Mann K; Kiefer F
Eur Neuropsychopharmacol; 2019 Dec; 29(12):1442-1452. PubMed ID: 31740271
[TBL] [Abstract][Full Text] [Related]
4. Effects of Varenicline on Neural Correlates of Alcohol Salience in Heavy Drinkers.
Vatsalya V; Gowin JL; Schwandt ML; Momenan R; Coe MA; Cooke ME; Hommer DW; Bartlett S; Heilig M; Ramchandani VA
Int J Neuropsychopharmacol; 2015 Jul; 18(12):. PubMed ID: 26209857
[TBL] [Abstract][Full Text] [Related]
5. Opioid receptor antagonism and neural response to monetary rewards: Pilot studies in light and heavy alcohol users.
Gowin JL; Sloan ME; Kirk-Provencher KT; Rosenblatt SL; Penner AE; Stangl BL; Byrd ND; Swan JE; Ramchandani VA
J Psychopharmacol; 2023 Sep; 37(9):937-941. PubMed ID: 37530456
[TBL] [Abstract][Full Text] [Related]
6. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity?
Bart G; Schluger JH; Borg L; Ho A; Bidlack JM; Kreek MJ
Neuropsychopharmacology; 2005 Dec; 30(12):2254-62. PubMed ID: 15988468
[TBL] [Abstract][Full Text] [Related]
7. Acute naltrexone does not remediate fronto-striatal disturbances in alcoholic and alcoholic polysubstance-dependent populations during a monetary incentive delay task.
Nestor LJ; Murphy A; McGonigle J; Orban C; Reed L; Taylor E; Flechais R; Paterson LM; Smith D; Bullmore ET; Ersche KD; Suckling J; Tait R; Elliott R; Deakin B; Rabiner I; Lingford-Hughes A; Nutt DJ; Sahakian B; Robbins TW;
Addict Biol; 2017 Nov; 22(6):1576-1589. PubMed ID: 27600363
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence.
Walker BM; Koob GF
Neuropsychopharmacology; 2008 Feb; 33(3):643-52. PubMed ID: 17473837
[TBL] [Abstract][Full Text] [Related]
9. Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential.
Soyka M
Expert Opin Pharmacother; 2016; 17(4):619-26. PubMed ID: 26810044
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacological profile and clinical findings of nalmefene (Selincro
Tadori Y
Nihon Yakurigaku Zasshi; 2020; 155(2):113-119. PubMed ID: 32115477
[TBL] [Abstract][Full Text] [Related]
11. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.
Gual A; He Y; Torup L; van den Brink W; Mann K;
Eur Neuropsychopharmacol; 2013 Nov; 23(11):1432-42. PubMed ID: 23562264
[TBL] [Abstract][Full Text] [Related]
12. [Alcohol dependence and opioid receptor -Pharmacological profile of nalmefene].
Ohgi Y
Nihon Yakurigaku Zasshi; 2020; 155(3):145-148. PubMed ID: 32378631
[TBL] [Abstract][Full Text] [Related]
13. Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy.
Mann K; Torup L; Sørensen P; Gual A; Swift R; Walker B; van den Brink W
Eur Neuropsychopharmacol; 2016 Dec; 26(12):1941-1949. PubMed ID: 27842940
[TBL] [Abstract][Full Text] [Related]
14. Continuous delivery of naltrexone and nalmefene leads to tolerance in reducing alcohol drinking and to supersensitivity of brain opioid receptors.
Korpi ER; Linden AM; Hytönen HR; Paasikoski N; Vashchinkina E; Dudek M; Herr DR; Hyytiä P
Addict Biol; 2017 Jul; 22(4):1022-1035. PubMed ID: 26990998
[TBL] [Abstract][Full Text] [Related]
15. Acute tramadol enhances brain activity associated with reward anticipation in the nucleus accumbens.
Asari Y; Ikeda Y; Tateno A; Okubo Y; Iijima T; Suzuki H
Psychopharmacology (Berl); 2018 Sep; 235(9):2631-2642. PubMed ID: 29951769
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.
Mason BJ; Salvato FR; Williams LD; Ritvo EC; Cutler RB
Arch Gen Psychiatry; 1999 Aug; 56(8):719-24. PubMed ID: 10435606
[TBL] [Abstract][Full Text] [Related]
17. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.
Mann K; Bladström A; Torup L; Gual A; van den Brink W
Biol Psychiatry; 2013 Apr; 73(8):706-13. PubMed ID: 23237314
[TBL] [Abstract][Full Text] [Related]
18. Nalmefene. Alcohol dependence: no advance.
Prescrire Int; 2014 Jun; 23(150):150-2. PubMed ID: 25121147
[TBL] [Abstract][Full Text] [Related]
19. Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.
Soyka M; Friede M; Schnitker J
Pharmacopsychiatry; 2016 Mar; 49(2):66-75. PubMed ID: 26845589
[TBL] [Abstract][Full Text] [Related]
20. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.
Mason BJ; Ritvo EC; Morgan RO; Salvato FR; Goldberg G; Welch B; Mantero-Atienza E
Alcohol Clin Exp Res; 1994 Oct; 18(5):1162-7. PubMed ID: 7847600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
